IL-33 Signaling Inhibition Leads to a Preeclampsia-Like Phenotype in Pregnant Rats

Overview

Journal Am J Reprod Immunol

Specialties Allergy & Immunology
Reproductive Medicine

Date 2024 Jul 13

PMID 39001587

Authors

Xi Wang

Corbin A Shields

Deanna Thompson

Jie McKay

Rachel Wilson

Marcus K Robbins

Hannah Glenn

Molly Fontenot

Jan M Williams

Denise C Cornelius

Affiliations

Soon will be listed here.

Abstract

Problem: Preeclampsia (PE) is a hypertensive pregnancy disorder that is a leading cause of maternal and fetal morbidity and mortality characterized by maternal vascular dysfunction, oxidative stress, chronic immune activation, and excessive inflammation. No cure exists beyond delivery of the fetal-placental unit and the mechanisms driving pathophysiology are not fully understood. However, aberrant immune responses have been extensively characterized in clinical studies and shown to mediate PE pathophysiology in animal studies. One pathway that may mediate aberrant immune responses in PE is deficiencies in the IL-33 signaling pathway. In this study, we aim to investigate the impact of IL-33 signaling inhibition on cNK, T17, and T populations, vascular function, and maternal blood pressure during pregnancy.

Method Of Study: In this study, IL-33 signaling was inhibited using two different methods: intraperitoneal administration of recombinant ST2 (which acts as a decoy receptor for IL-33) and administration of a specific IL-33 neutralizing antibody. Maternal blood pressure, uterine artery resistance index, renal and placental oxidative stress, cNK, T17, and T populations, various cytokines, and pre-proendothelin-1 levels were measured.

Results: IL-33 signaling inhibition increased maternal blood pressure, uterine artery resistance, placental and renal oxidative stress. IL-33 signaling inhibition also increased placental cNK and T17 and renal T17 cells while decreasing placental T populations. IL-33 neutralization increased circulating cNK and T17s and decreased circulating Ts in addition to increasing pre-proendothelin-1 levels.

Conclusions: Data presented in this study demonstrate a role for IL-33 signaling in controlling vascular function and maternal blood pressure during pregnancy possibly by mediating innate and adaptive immune inflammatory responses, identifying the IL-33 signaling pathway as a potential therapeutic target for managing preeclampsia.

References

Wang Z, Tang N . Unpacking the complexity of nuclear IL-33 (nIL-33): a crucial regulator of transcription and signal transduction. J Cell Commun Signal. 2023; 17(4):1131-1143. PMC: 10713911. DOI: 10.1007/s12079-023-00788-1. View

Aggarwal R, Jain A, Mittal P, Kohli M, Jawanjal P, Rath G . Association of pro- and anti-inflammatory cytokines in preeclampsia. J Clin Lab Anal. 2019; 33(4):e22834. PMC: 6528584. DOI: 10.1002/jcla.22834. View

Zhang H, Wu M, Lin Y, Xie S, Huang T, Liu P . IL-33 promotes IL-10 production in macrophages: a role for IL-33 in macrophage foam cell formation. Exp Mol Med. 2017; 49(11):e388. PMC: 5704190. DOI: 10.1038/emm.2017.183. View

Nascimento D, Melo P, Pineros A, Ferreira R, Colon D, Donate P . IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population. Nat Commun. 2017; 8:14919. PMC: 5382289. DOI: 10.1038/ncomms14919. View

Travis O, White D, Baik C, Giachelli C, Thompson W, Stubbs C . Interleukin-17 signaling mediates cytolytic natural killer cell activation in response to placental ischemia. Am J Physiol Regul Integr Comp Physiol. 2020; 318(6):R1036-R1046. PMC: 7311683. DOI: 10.1152/ajpregu.00285.2019. View

Wang X, Travis O, Shields C, Tardo G, Giachelli C, Nutter C . NLRP3 inhibition improves maternal hypertension, inflammation, and vascular dysfunction in response to placental ischemia. Am J Physiol Regul Integr Comp Physiol. 2023; 324(4):R556-R567. PMC: 10069976. DOI: 10.1152/ajpregu.00192.2022. View

Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R . Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014; 10(8):466-80. PMC: 5893150. DOI: 10.1038/nrneph.2014.102. View

Phipps E, Thadhani R, Benzing T, Karumanchi S . Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019; 15(5):275-289. PMC: 6472952. DOI: 10.1038/s41581-019-0119-6. View

Chen H, Zhou X, Han T, Baker P, Qi H, Zhang H . Decreased IL-33 Production Contributes to Trophoblast Cell Dysfunction in Pregnancies with Preeclampsia. Mediators Inflamm. 2018; 2018:9787239. PMC: 5875049. DOI: 10.1155/2018/9787239. View

10.

Mehraj V, Ponte R, Routy J . The Dynamic Role of the IL-33/ST2 Axis in Chronic Viral-infections: Alarming and Adjuvanting the Immune Response. EBioMedicine. 2016; 9:37-44. PMC: 4972565. DOI: 10.1016/j.ebiom.2016.06.047. View

11.

Alexander B, Cockrell K, Massey M, Bennett W, Granger J . Tumor necrosis factor-alpha-induced hypertension in pregnant rats results in decreased renal neuronal nitric oxide synthase expression. Am J Hypertens. 2002; 15(2 Pt 1):170-5. DOI: 10.1016/s0895-7061(01)02255-5. View

12.

Xu H, Turnquist H, Hoffman R, Billiar T . Role of the IL-33-ST2 axis in sepsis. Mil Med Res. 2017; 4:3. PMC: 5288881. DOI: 10.1186/s40779-017-0115-8. View

13.

Chen Z, Wu C, Liu Y, Li H, Zhu Y, Huang C . ELABELA attenuates deoxycorticosterone acetate/salt-induced hypertension and renal injury by inhibition of NADPH oxidase/ROS/NLRP3 inflammasome pathway. Cell Death Dis. 2020; 11(8):698. PMC: 7443189. DOI: 10.1038/s41419-020-02912-0. View

14.

Wang X, Shields C, Tardo G, Peacock G, Hester E, Anderson M . IL-33 supplementation improves uterine artery resistance and maternal hypertension in response to placental ischemia. Am J Physiol Heart Circ Physiol. 2024; 326(4):H1006-H1016. PMC: 11279736. DOI: 10.1152/ajpheart.00045.2024. View

15.

Ibrahim T, Przybyl L, Harmon A, Amaral L, Faulkner J, Cornelius D . Proliferation of endogenous regulatory T cells improve the pathophysiology associated with placental ischaemia of pregnancy. Am J Reprod Immunol. 2017; 78(5). PMC: 5916789. DOI: 10.1111/aji.12724. View

16.

Collier A, Molina R . Maternal Mortality in the United States: Updates on Trends, Causes, and Solutions. Neoreviews. 2019; 20(10):e561-e574. PMC: 7377107. DOI: 10.1542/neo.20-10-e561. View

17.

Travis O, Tardo G, Giachelli C, Siddiq S, Nguyen H, Crosby M . Tumor Necrosis Factor-alpha Blockade Improves Uterine Artery Resistance, Maternal Blood Pressure, and Fetal Growth in Placental Ischemic Rats. Pregnancy Hypertens. 2021; 25:39-47. PMC: 8363517. DOI: 10.1016/j.preghy.2021.05.002. View

18.

Geldenhuys J, Rossouw T, Lombaard H, Ehlers M, Kock M . Disruption in the Regulation of Immune Responses in the Placental Subtype of Preeclampsia. Front Immunol. 2018; 9:1659. PMC: 6062603. DOI: 10.3389/fimmu.2018.01659. View

19.

Liu Y, Yin H, Li C, Jiang F, Zhang S, Zhang X . Sinapine Thiocyanate Ameliorates Vascular Endothelial Dysfunction in Hypertension by Inhibiting Activation of the NLRP3 Inflammasome. Front Pharmacol. 2021; 11:620159. PMC: 7901921. DOI: 10.3389/fphar.2020.620159. View

20.

Choi Y, Park J, Kim J, Rho S, Park H, Kim Y . Nuclear IL-33 is a transcriptional regulator of NF-κB p65 and induces endothelial cell activation. Biochem Biophys Res Commun. 2012; 421(2):305-11. DOI: 10.1016/j.bbrc.2012.04.005. View